These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 29097261)

  • 1. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
    Nussinov R; Zhang M; Tsai CJ; Jang H
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calmodulin and PI3K Signaling in
    Nussinov R; Wang G; Tsai CJ; Jang H; Lu S; Banerjee A; Zhang J; Gaponenko V
    Trends Cancer; 2017 Mar; 3(3):214-224. PubMed ID: 28462395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
    Nussinov R; Tsai CJ; Jang H
    Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas.
    Nussinov R; Muratcioglu S; Tsai CJ; Jang H; Gursoy A; Keskin O
    Mol Cancer Res; 2015 Sep; 13(9):1265-73. PubMed ID: 26085527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flexible-body motions of calmodulin and the farnesylated hypervariable region yield a high-affinity interaction enabling K-Ras4B membrane extraction.
    Jang H; Banerjee A; Chavan T; Gaponenko V; Nussinov R
    J Biol Chem; 2017 Jul; 292(30):12544-12559. PubMed ID: 28623230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?
    Nussinov R; Muratcioglu S; Tsai CJ; Jang H; Gursoy A; Keskin O
    Expert Opin Ther Targets; 2016 Jul; 20(7):831-42. PubMed ID: 26873344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylated Calmodulin Promotes PI3K Activation by Binding to the SH
    Zhang M; Jang H; Gaponenko V; Nussinov R
    Biophys J; 2017 Nov; 113(9):1956-1967. PubMed ID: 29117520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic Ras Isoforms Signaling Specificity at the Membrane.
    Nussinov R; Tsai CJ; Jang H
    Cancer Res; 2018 Feb; 78(3):593-602. PubMed ID: 29273632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
    Huang L; Counter CM
    PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calmodulin (CaM) Activates PI3Kα by Targeting the "Soft" CaM-Binding Motifs in Both the nSH2 and cSH2 Domains of p85α.
    Zhang M; Li Z; Wang G; Jang H; Sacks DB; Zhang J; Gaponenko V; Nussinov R
    J Phys Chem B; 2018 Dec; 122(49):11137-11146. PubMed ID: 30047727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions.
    Nakhaeizadeh H; Amin E; Nakhaei-Rad S; Dvorsky R; Ahmadian MR
    PLoS One; 2016; 11(12):e0167145. PubMed ID: 27936046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Structural Basis of the Farnesylated and Methylated KRas4B Interaction with Calmodulin.
    Jang H; Banerjee A; Marcus K; Makowski L; Mattos C; Gaponenko V; Nussinov R
    Structure; 2019 Nov; 27(11):1647-1659.e4. PubMed ID: 31495533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
    Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
    Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insight into the mechanism of allosteric activation of PI3Kα by oncoprotein K-Ras4B.
    Li X; Dai J; Ni D; He X; Zhang H; Zhang J; Fu Q; Liu Y; Lu S
    Int J Biol Macromol; 2020 Feb; 144():643-655. PubMed ID: 31816384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ca
    Zhang M; Li Z; Jang H; Hedman AC; Sacks DB; Nussinov R
    Biochemistry; 2019 Dec; 58(49):4903-4911. PubMed ID: 31724397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth.
    Tang R; Shuldiner EG; Kelly M; Murray CW; Hebert JD; Andrejka L; Tsai MK; Hughes NW; Parker MI; Cai H; Li YC; Wahl GM; Dunbrack RL; Jackson PK; Petrov DA; Winslow MM
    Nat Cell Biol; 2023 Jan; 25(1):159-169. PubMed ID: 36635501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Specificity of EGF-Stimulated IQGAP1 Scaffold Towards the PI3K-Akt Pathway is Defined by the IQ3 motif.
    Chen M; Choi S; Jung O; Wen T; Baum C; Thapa N; Lambert PF; Rapraeger AC; Anderson RA
    Sci Rep; 2019 Jun; 9(1):9126. PubMed ID: 31235839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of liver oncogenic potential among human RAS isoforms.
    Chung SI; Moon H; Ju HL; Kim DY; Cho KJ; Ribback S; Dombrowski F; Calvisi DF; Ro SW
    Oncotarget; 2016 Feb; 7(6):7354-66. PubMed ID: 26799184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The structural basis of Akt PH domain interaction with calmodulin.
    Weako J; Jang H; Keskin O; Nussinov R; Gursoy A
    Biophys J; 2021 May; 120(10):1994-2008. PubMed ID: 33775637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.
    Grabocka E; Pylayeva-Gupta Y; Jones MJ; Lubkov V; Yemanaberhan E; Taylor L; Jeng HH; Bar-Sagi D
    Cancer Cell; 2014 Feb; 25(2):243-56. PubMed ID: 24525237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.